A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability

Human Reproduction

Volumn 22, Issue 4, 2007, Pages 1186-1191

  Skouby, Sven O ^a,c   Sidelmann, Johannes J ^c   Nilas, Lisbeth ^b   Jespersen, Jørgen ^c,d  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d ESBJERG HOSPITAL   (Denmark)

Author keywords

Coagulation; Conjugated equine estrogen; Medroxyprogesterone acetate; Tibolone; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TIBOLONE; TISSUE FACTOR PATHWAY INHIBITOR; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; HEMOSTASIS; HORMONAL THERAPY; HUMAN; PHARMACODYNAMICS; POSTMENOPAUSE; RISK FACTOR; STATISTICAL ANALYSIS; VENOUS THROMBOEMBOLISM; AGED; ANIMAL; HORSE; MIDDLE AGED; THROMBOEMBOLISM; VEIN THROMBOSIS;

EQUIDAE;

AGED; ANIMALS; BLOOD COAGULATION; ESTROGEN RECEPTOR MODULATORS; ESTROGENS, CONJUGATED (USP); FEMALE; HEMOSTASIS; HORSES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34347258500     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del498     Document Type: Article

References (32)

1. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ and Ariens RA (2001) Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 113,537-543.
2. Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ and Christiansen C (1997) Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 82,1752-1756.
3. Bladbjerg EM, Skouby SO, Andersen LF and Jespersen J (2002) Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 17,3235-3241.
4. Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L and Jespersen J (2003) Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 1,1208-1214.
5. Cortes-Prieto J (1987) Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. Maturitas (Suppl 1),67-72.
6. Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM and Sandset PM (2003) Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101, 4387-4392.
7. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P and Marsh S (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348,977-980.
8. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, Barone M, Piovella F, Turpie AG, Middeldorp S et al. (2005) Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 3,943-948.
9. Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC and Sandset PM (2001) The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial. Thromb Haemost 85,775-781.
10. Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, Kollars M, Weltermann A and Eichinger S (2005) Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 94,787-790.
11. Jackson G (2001) Tibolone and the cardiovascular system. Eur Heart J 3 Suppl, M17-M21.
12. Koh KK, Ahn JY, Jin DK, Yoon BK, Kim HS, Kim DS, Kang WC, Han SH, Choi IS and Shin EK (2003) Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 23,1889-1894.
13. Koh KK, Han SH, Shin MS, Ahn JY, Lee Y and Shin EK (2005) Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 26,1362-1368.
14. Lobo RA, Bush T, Carr BR and Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76,13-24.
15. Lowe GD (2004) Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med 256,361-374.
16. Norris LA, Joyce M, O'Keeffe N, Sheppard BL and Bonnar J (2002) Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 43,125-133.
17. Nozaki M, Ogata R, Koera K, Hashimoto K and Nakano H (1999) Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric 2,124-130.
18. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, Okumus B and Bozkaya H (2005) Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 84,384-393.
19. Parkin DE, Smith D, Al Azzawi F, Lindsay R and Hart DM (1987) Effects of long-term Org OD 14 administration on blood coagulation in climacteric women. Maturitas 9,95-101.
20. Perez GS, Garcia Rodriguez LA, Castellsague J and Duque OA (1997) Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 314,796-800.
21. Peverill RE (2003) Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 17,149-164.
22. Rosen SB and Sturk A (1997) Activated protein C resistance - a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem 35,501-516.
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333.
24. Salobir BG, Keber I and Vrabic L (2002) A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril 78,1178-1183.
25. Scarabin PY, Oger E and Plu-Bureau G (2003) Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362,428-432.
26. Sidelmann JJ, Jespersen J, Andersen LF and Skouby SO (2003) Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG 110,541-547.
27. Sumino H, Ichikawa S, Sawada Y, Sakamoto H, Kumakura H, Takayama Y, Sakamaki T and Kurabayashi M (2005) Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thromb Res 115,359-366.
28. The Writing Group for the 3rd European Conference on Sex Steroids and Cardiovascular Diseases (2003). The European Consensus Development Conference 2002: Sex Steroids and Cardiovascular Diseases. On the route to combined evidence from OC and HRT/ERT. Maturitas 44,69-82.
29. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L and Perez-Gutthann S (1998) Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 147,387-390.
30. Walker ID, Davidson JF, Richards A, Yates R and McEwan HP (1985) The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost 53,303-305.
31. van Wersch JW, Ubachs JM, van den Ende A and van Enk A (1994) The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem 32,449-453.
32. Winkler UH, Altkemper R, Kwee B, Helmond FA and Coelingh Bennink HJ (2000) Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 74,10-19.